vs
Side-by-side financial comparison of GLADSTONE COMMERCIAL CORP (GOOD) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $43.5M, roughly 1.3× GLADSTONE COMMERCIAL CORP). GLADSTONE COMMERCIAL CORP runs the higher net margin — 12.4% vs -83.0%, a 95.4% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 16.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 10.3%).
Gladstone Commercial Corp is a publicly traded US real estate investment trust focused on acquiring, owning, and operating diversified industrial and commercial properties. It offers long-term net lease agreements to tenants across manufacturing, logistics, healthcare and professional services sectors, mainly serving small to mid-sized business clients.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
GOOD vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $57.3M |
| Net Profit | $5.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 12.4% | -83.0% |
| Revenue YoY | 16.3% | 36.9% |
| Net Profit YoY | -25.1% | -9.6% |
| EPS (diluted) | $0.05 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $57.3M | ||
| Q3 25 | $40.8M | $51.3M | ||
| Q2 25 | $39.5M | $48.5M | ||
| Q1 25 | $37.5M | $32.7M | ||
| Q4 24 | $37.4M | $41.8M | ||
| Q3 24 | $39.2M | $33.3M | ||
| Q2 24 | $37.1M | $29.1M | ||
| Q1 24 | $35.7M | $26.0M |
| Q4 25 | $5.4M | $-47.5M | ||
| Q3 25 | $4.1M | $-52.9M | ||
| Q2 25 | $4.6M | $-46.6M | ||
| Q1 25 | $5.1M | $-49.5M | ||
| Q4 24 | $7.2M | $-43.3M | ||
| Q3 24 | $11.7M | $-43.6M | ||
| Q2 24 | $1.6M | $-32.3M | ||
| Q1 24 | $3.5M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | 12.4% | -83.0% | ||
| Q3 25 | 10.1% | -103.1% | ||
| Q2 25 | 11.7% | -96.1% | ||
| Q1 25 | 13.7% | -151.4% | ||
| Q4 24 | 19.2% | -103.6% | ||
| Q3 24 | 29.8% | -131.2% | ||
| Q2 24 | 4.3% | -110.9% | ||
| Q1 24 | 9.9% | -544.4% |
| Q4 25 | $0.05 | $-0.73 | ||
| Q3 25 | $0.02 | $-0.82 | ||
| Q2 25 | $0.03 | $-0.75 | ||
| Q1 25 | $0.04 | $-0.81 | ||
| Q4 24 | $0.10 | $-0.71 | ||
| Q3 24 | $0.20 | $-0.73 | ||
| Q2 24 | $-0.04 | $-0.55 | ||
| Q1 24 | $0.01 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.8M | $388.9M |
| Total DebtLower is stronger | $843.5M | — |
| Stockholders' EquityBook value | $171.8M | $139.1M |
| Total Assets | $1.2B | $480.2M |
| Debt / EquityLower = less leverage | 4.91× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.8M | $388.9M | ||
| Q3 25 | $18.4M | $416.1M | ||
| Q2 25 | $11.7M | $291.0M | ||
| Q1 25 | $10.4M | $314.5M | ||
| Q4 24 | $11.0M | $320.6M | ||
| Q3 24 | $10.5M | $298.4M | ||
| Q2 24 | $10.4M | $319.1M | ||
| Q1 24 | $10.5M | $201.2M |
| Q4 25 | $843.5M | — | ||
| Q3 25 | $843.3M | — | ||
| Q2 25 | $794.4M | — | ||
| Q1 25 | $740.7M | — | ||
| Q4 24 | $693.4M | — | ||
| Q3 24 | $692.6M | — | ||
| Q2 24 | $722.5M | — | ||
| Q1 24 | $719.4M | — |
| Q4 25 | $171.8M | $139.1M | ||
| Q3 25 | $184.8M | $148.8M | ||
| Q2 25 | $177.2M | $-11.9M | ||
| Q1 25 | $183.2M | $18.9M | ||
| Q4 24 | $171.2M | $21.7M | ||
| Q3 24 | $168.9M | $11.2M | ||
| Q2 24 | $145.7M | $39.3M | ||
| Q1 24 | $147.3M | $61.6M |
| Q4 25 | $1.2B | $480.2M | ||
| Q3 25 | $1.3B | $506.9M | ||
| Q2 25 | $1.2B | $372.7M | ||
| Q1 25 | $1.2B | $386.7M | ||
| Q4 24 | $1.1B | $392.3M | ||
| Q3 24 | $1.1B | $363.6M | ||
| Q2 24 | $1.1B | $381.8M | ||
| Q1 24 | $1.1B | $258.7M |
| Q4 25 | 4.91× | — | ||
| Q3 25 | 4.56× | — | ||
| Q2 25 | 4.48× | — | ||
| Q1 25 | 4.04× | — | ||
| Q4 24 | 4.05× | — | ||
| Q3 24 | 4.10× | — | ||
| Q2 24 | 4.96× | — | ||
| Q1 24 | 4.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $88.2M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 16.38× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $88.2M | $-25.4M | ||
| Q3 25 | $18.9M | $-26.6M | ||
| Q2 25 | $35.8M | $-23.3M | ||
| Q1 25 | $17.7M | $-40.4M | ||
| Q4 24 | $57.0M | $-18.8M | ||
| Q3 24 | $5.5M | $-25.2M | ||
| Q2 24 | $13.6M | $-29.1M | ||
| Q1 24 | $15.0M | $-40.7M |
| Q4 25 | 16.38× | — | ||
| Q3 25 | 4.57× | — | ||
| Q2 25 | 7.74× | — | ||
| Q1 25 | 3.44× | — | ||
| Q4 24 | 7.93× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 8.44× | — | ||
| Q1 24 | 4.26× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
